- Home
- BBIO vs VANI Comparison
BBIO vs VANI Comparison
Compare BBIO & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBIO
- VANI
- Stock Information
- Founded
- BBIO 2015
- VANI 1998
- Country
- BBIO United States
- VANI United States
- Employees
- BBIO N/A
- VANI N/A
- Industry
- BBIO Biotechnology: Pharmaceutical Preparations
- VANI Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- BBIO Health Care
- VANI Health Care
- Exchange
- BBIO Nasdaq
- VANI Nasdaq
- Market Cap
- BBIO 6.7B
- VANI N/A
- IPO Year
- BBIO 2019
- VANI 2014
- Fundamental
- Price
- BBIO $34.17
- VANI $1.04
- Analyst Decision
- BBIO Strong Buy
- VANI Strong Buy
- Analyst Count
- BBIO 12
- VANI 1
- Target Price
- BBIO $57.09
- VANI $4.00
- AVG Volume (30 Days)
- BBIO 3.1M
- VANI 40.6K
- Earning Date
- BBIO 04-29-2025
- VANI 05-20-2025
- Dividend Yield
- BBIO N/A
- VANI N/A
- EPS Growth
- BBIO N/A
- VANI N/A
- EPS
- BBIO N/A
- VANI N/A
- Revenue
- BBIO $127,415,000.00
- VANI N/A
- Revenue This Year
- BBIO $13.67
- VANI N/A
- Revenue Next Year
- BBIO $118.02
- VANI N/A
- P/E Ratio
- BBIO N/A
- VANI N/A
- Revenue Growth
- BBIO N/A
- VANI N/A
- 52 Week Low
- BBIO $21.62
- VANI $0.91
- 52 Week High
- BBIO $39.47
- VANI $2.09
- Technical
- Relative Strength Index (RSI)
- BBIO 44.19
- VANI 49.96
- Support Level
- BBIO $33.92
- VANI $1.02
- Resistance Level
- BBIO $39.16
- VANI $1.07
- Average True Range (ATR)
- BBIO 1.50
- VANI 0.02
- MACD
- BBIO -0.24
- VANI 0.00
- Stochastic Oscillator
- BBIO 10.35
- VANI 52.63
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.